The Role of Adjuvant Albendazole After Pulmonary Hydatid Cyst Resection: a Randomised Controlled Trial
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The aim of this study is to study the role of adjuvant Albendazole after pulmonary hydatid cyst resection versus placebo in reducing recurrence with a short- term follow-up of six months.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: t
View:
• All patients regardless of age with pulmonary hydatid disease requiring surgical resection.
• Patients achieving complete resection of pulmonary hydatid disease.
• Patients with no extra pulmonary hydatid disease.
• Patients who have received preoperative albendazole.
Locations
Other Locations
Egypt
Ain Shams University Hospitals
RECRUITING
Cairo
Time Frame
Start Date: 2024-02-01
Estimated Completion Date: 2025-07-01
Participants
Target number of participants: 24
Treatments
Active_comparator: Albendazole arm
The administration of albendazole therapy is recommended at a dosage of 15 mg/kg/day, given in two equally split doses per day. This is within two 15-day cycles following surgery.
Placebo_comparator: Placebo arm
Patients will receive the placebo, which will be in two equally split doses per day. This is within two 15-day cycles following surgery.
Related Therapeutic Areas
Sponsors
Leads: Ain Shams University